Suliqua (insulin glargine;lixisenatide)
- Region
- 🇪🇺 EU
- Active substance
- insulin glargine;lixisenatide
- Company
- Sanofi Winthrop Industrie
- Status
- Authorised
- Therapeutic area
- Diabetes Mellitus, Type 2
- CHMP opinion
- Thu 10 Nov 2016
- EU approval
- Wed 11 Jan 2017
- Application
- EMEA/H/C/004243
- ATC
- A10AE54
- Official record
- www.ema.europa.eu
Indication
Suliqua is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise in addition to metformin with or without SGLT-2 inhibitors.
Regulatory milestones
No milestones recorded in the last year.
Follow Suliqua
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.